



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Lidocaine Topical Patch Page: 1 of 2

Effective Date: 12/16/2022 Last Review Date: 3/2022

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input checked="" type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for lidocaine topical patch under the member's prescription drug benefit.

### Description:

#### Lidoderm

Lidoderm is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to **intact skin**.

### Applicable Drug List:

Formulary Drug: Lidocaine 5% patch

Formulary Drug: Lidocaine 4% Patch Over-The-Counter (OTC)

### Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for pain associated with post-herpetic neuralgia

Quantity Limits apply.

### Approval Duration and Quantity Restrictions:

**Approval:** 12 months

**Quantity Level Limit:** 90 patches/25 days

### References:

1. Lidoderm [package insert]. Malvern, PA: Endo Pharmaceuticals Inc.; January 2020.
2. ZTLido [package insert]. Palo Alto, CA: Scilex Pharmaceuticals Inc.; April 2021.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed September 2, 2021.
4. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed September 2, 2021.
5. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic Management of Neuropathic Pain: Evidence-based recommendations. *Pain*. 2007;132(3):237-251.



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Lidocaine Topical Patch Page: 2 of 2

Effective Date: 12/16/2022 Last Review Date: 3/2022

Applies to:  Illinois  Florida  Florida Kids  
 New Jersey  Maryland  Michigan  
 Pennsylvania Kids  Virginia

6. Saguil A, Kane S, Mercado M, et al. Herpes Zoster and Postherpetic Neuralgia: Prevention and Management. *Am Fam Physician*. 2017;96(10):656-663.
7. Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2004;63(6):959-65.  
<http://www.neurology.org/content/neurology/63/6/959.full.pdf>. Accessed September 2021.